Search research articles
Contact Us
Filters
Showing results (51-60 of 122) with videos related to
Page
of 13
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
Johannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
Cancer
|
August 22, 2019
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study
Elias J Jabbour, Nicola Gökbuget, Hagop M Kantarjian, et al.
Blood
|
July 14, 2010
Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation
Tobias Feuchtinger, Kathrin Opherk, Wolfgang A Bethge, et al.
Blood
|
August 2, 2015
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
Fritz Offner, Olga Samoilova, Evgenii Osmanov, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 9, 2023
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [<sup>18</sup>F]FDG
Aleksander Kosmala, Johannes Duell, Simone Schneid, et al.
Leukemia & Lymphoma
|
July 4, 2020
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia
Nicola Gökbuget, Gerhard Zugmaier, Hervé Dombret, et al.
Blood Advances
|
January 29, 2026
Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma
Julia Mersi, Lara Burow, Xiang Zhou, et al.
The Lancet. Haematology
|
March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)
Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
Molecular Imaging and Biology
|
August 1, 2024
Interobserver Agreement Rates on CXCR4-Directed PET/CT in Patients with Marginal Zone Lymphoma
Rudolf A Werner, Yingjun Zhi, Niklas Dreher, et al.
JAMA Oncology
|
February 5, 2026
BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma
Justin Ferdinandus, Horst Müller, Janina Jablonski, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 122) with videos related to
Sort By:
Page
of 13
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
Johannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
Cancer
|
August 22, 2019
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study
Elias J Jabbour, Nicola Gökbuget, Hagop M Kantarjian, et al.
Blood
|
July 14, 2010
Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation
Tobias Feuchtinger, Kathrin Opherk, Wolfgang A Bethge, et al.
Blood
|
August 2, 2015
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
Fritz Offner, Olga Samoilova, Evgenii Osmanov, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 9, 2023
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [<sup>18</sup>F]FDG
Aleksander Kosmala, Johannes Duell, Simone Schneid, et al.
Leukemia & Lymphoma
|
July 4, 2020
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia
Nicola Gökbuget, Gerhard Zugmaier, Hervé Dombret, et al.
Blood Advances
|
January 29, 2026
Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma
Julia Mersi, Lara Burow, Xiang Zhou, et al.
The Lancet. Haematology
|
March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)
Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
Molecular Imaging and Biology
|
August 1, 2024
Interobserver Agreement Rates on CXCR4-Directed PET/CT in Patients with Marginal Zone Lymphoma
Rudolf A Werner, Yingjun Zhi, Niklas Dreher, et al.
JAMA Oncology
|
February 5, 2026
BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma
Justin Ferdinandus, Horst Müller, Janina Jablonski, et al.
Page
of 13